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MEETING REPORT Open Access
Ethical considerations in an era of mass
drug administration
Barney Wharam* and Luke Lazarou
Abstract
In a Plenary debate at the 51st Spring meeting of the British Society of Parasitology, Bristol, UK, April 8–11, 2013, the
bioethicist James Wilson used the value of a life in the present and future to question the effectiveness of current
health strategies.
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Main text
A debate during the 51st spring meeting of the British
Society of Parasitology, Bristol, UK, April 8–11, 2013, con-
sidered the broader ethical and practical issues of current
strategies used in controlling parasites worldwide.
For thousands of years humans have attempted to
treat the infections that were ubiquitous in their com-
munities. With the advent of improved sanitation and
advances in medicine, parasitic infections rarely impact
on human life in the developed world. This contrasts
with the developing world where to be infected is still
normal in many communities. In sub-Saharan Africa at
least 500 million people are affected by Neglected Trop-
ical Diseases (NTDs). The current control strategy in
sub-Saharan Africa involves large multi-million dollar
programmes of mass drug administration, in which
whole populations are treated regardless of whom is
infected. Such widespread, prolonged use of chemother-
apy comes with its own problems. What is the best
long-term answer for humanity to address such a huge
burden of disease? Do we attempt to treat these para-
sites through the same means as we did in the developed
world, or are there other, better ways?
Ethical considerations in treating disease
Is a life in the future worth less than a life in the
present? James Wilson (University College London)
pointed out that many current health strategies impli-
citly assume that saving a life now is more important
than saving a life in the future, for example until recently
the World Health Organisation’s Global Burden of Dis-
ease project discounted the value of future lives. The
logic of these health strategies normally involves the un-
certainty of the future. Because we have no real way of
predicting the state of future populations, unforeseen
events such as war or emerging diseases may make in-
vestments in the future worthless.
Despite this, are current policy makers really making
decisions that benefit the most people irrespective of
when they live? If all human life is valued equally,
healthcare resources should ideally be used in a way that
maximises the health benefit for the largest number of
people. Wilson highlighted the fact that if present and
future lives were given equal weight, then perhaps the
most ethical course of action would be to invest most of
our resources now to eradicate diseases, where possible,
and therefore to save countless future lives. Even if at-
tempts at eradication of a parasitic infection might ul-
timately fail, then this is not a reason not to try,
because the benefits of success are so large. Further-
more, even failed attempts at eradication can lead to
large populations being relieved of their burden of dis-
ease if only temporarily.
Drug resistance and the future
Programmes that aim to eradicate parasites through
chemotherapy have their own risks in the form of drug
resistance. The evolution of widespread drug resistance
in parasites population both renders a drug impotent
and reduces our ability to treat disease. This is especially
problematic if there are only one or a few drugs effective
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against a parasite. The emerging problem of antibiotic
resistance was used as a current, real world example of
drug resistance by both Wilson and Andrew Read
(Pennsylvania State University).
Read illustrated the problems of drug resistance
through his recent visit to a Michigan hospital, where
patients are dying from “superbugs” - bacteria that are
resistant to many or all antibiotics that are available. Pa-
tients alive now are put into jeopardy because of actions
from the past. Antibiotic resistance demonstrates how
past health care policies did not sufficiently account for
the evolution of parasites and therefore discounted the
value of future lives inappropriately.
Read argued that there is a lack of research on how to
use drugs whilst minimising the evolution of drug resist-
ance. Drug resistance is also a key issue in veterinary
science and the fields of human and veterinary medicine
have become so distinct that veterinary studies are rarely
used to inform human medicine. Movements such as The
One Health Initiative (http://www.onehealthinitiative.com/
index.php) were highlighted by Read as a possible way
forward. The initiative aims to improve global healthcare
through interdisciplinary collaborations.
The era of mass drug administration
Alan Fenwick (Imperial College and Director of the
Schistosomiasis Control Initiative) summarized the
major global initiatives to control or eliminate NTDs,
which has led to four major pharmaceutical companies
(GlaxoSmithKline, Merck, Pfizer and Johnson & Johnson)
donating substantial quantities of drugs for the control of
5 NTDs. Fenwick explained that the control and treat-
ment of onchocerciasis has virtually eliminated blindness
due to onchocerciasis from West Africa. However, for this
success to be maintained, 100 million people must be
treated annually.
If mass drug administration programmes succeed in
breaking cycles of transmission they can be effective in
controlling and perhaps even eradicating diseases. Even
if eradication is not possible it may still be effective at
reducing the burden of disease for future generations.
However, Read argued that anthelminthic drugs will
eventually fail due to resistance evolving, pointing to
previous failures of antibiotics, antimalarial drugs and
pesticides. The World Health Organization current pol-
icy is that drugs will eventually fail. Read urged us not to
think of drugs as magic bullets but instead to realise that
they are stop-gap measures.
Perhaps the question is not will resistance develop, but
actually can we use strategies that make these drugs last
until other factors eliminate disease? A comment from the
audience raised the point that these diseases may never be
properly controlled until we have effective sanitation and
hygiene in the affected communities. Perhaps a more
integrated approach will be successful in the long term
whilst benefitting people now. As an example of this,
Fenwick highlighted a recent Bill and Melinda Gates
Foundation Conference, “Finding Synergies between
Water, Sanitation, and Hygiene (WASH) and the Con-
trol of Neglected Tropical Diseases (NTDs): Practical
Considerations to Collaboration Between the WASH
and NTD Sectors.”
If each and every human life is of equal value we should
all have access to treatment. If a life in the future and a life
in the present are of equal value then we need to act in a
way that treats people now as well as being responsible to
people in the future. If withdrawing treatment from people
alive now actually benefitted more lives in the future
should we do it? The reality is that we are not able to pre-
dict the future. Can we justify stopping mass drug admin-
istration on the basis of unquantifiable risk? How can we
change mass drug administration to minimise that risk?
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